Advertisement
Advertisement
U.S. markets open in 1 hour 24 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Biocept, Inc. (BIOC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6750-0.0375 (-5.26%)
At close: 04:00PM EST
0.7298 +0.05 (+8.12%)
Pre-Market: 07:00AM EST
Advertisement

Biocept, Inc.

9955 Mesa Rim Road
San Diego, CA 92121
United States
858 320 8200
https://biocept.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees177

Key Executives

NameTitlePayExercisedYear Born
Mr. Samuel D. RiccitelliInterim Pres, CEO & Chairman67.24kN/A1959
Mr. Antonino MoralesInterim CFO & Director20.76kN/A1956
Dr. Michael C. Dugan M.D.Sr. VP, Chief Medical Officer & Medical Director413.31kN/A1963
Dr. Soon Kap Hahn Ph.D.FounderN/AN/AN/A
Dr. Philippe J. Marchand Ph.D.Chief Operating OfficerN/AN/A1963
Mr. Pavel TsinbergDirector of Technology Devel.N/AN/AN/A
Mr. Darrell Taylor Esq.Sr. VP, Chief Legal Officer & Chief Compliance OfficerN/AN/A1965
Mr. David S. Moskowitz R.Ph., MBAVP of Strategy & Corp. CommunicationsN/AN/AN/A
Mr. Michael TerrySr. VP of Corp. Devel.N/AN/A1955
Antonio PaternostroVP of SalesN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Corporate Governance

Biocept, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement